Jim Cramer praises Walgreens new CEO pick, says buy the stock ‘perhaps aggressively’

Jim Cramer praises Walgreens new CEO pick, says buy the stock ‘perhaps aggressively’


Cramer’s Mad Dash on Walgreens Boots: The stock should be bought 'perhaps aggressively'

CNBC’s Jim Cramer on Wednesday praised the incoming CEO of Walgreens Boots Alliance, saying industry veteran Tim Wentworth is the right choice to lead the struggling pharmacy chain in its transition to offering more health-care services.

“This guy is the real deal. I just salute him and think he can take you to a higher price, and the stock should be bought — perhaps aggressively,” Cramer said on “Squawk on the Street.”

Wentworth, whose appointment was announced Thursday night, previously served as CEO of Express Scripts, a pharmacy benefits manager acquired by health insurer Cigna in 2018. He stayed on for a few years as an executive at Cigna.

If you like this story, sign up for Jim Cramer’s Top 10 Morning Thoughts on the Market email newsletter for free.

Wentworth’s first day at Walgreens is set for Oct. 23, less than two months after former chief executive Roz Brewer left her post. The company said it was seeking a new CEO who had “deep” experience in the health-care industry.

Shares of Walgreens rose more than 1% Wednesday, to $22.66. However, so far in 2023, the Dow Jones Industrial Average constituent is down nearly 40%.

“I like Wentworth, and there is now hope for a stock that I held no hope for,” Cramer said.

The CNBC Investing Club portfolio does not own Walgreens but does have some exposure to health-care services via Amazon, which bought a primary care company and has an online prescription drug store.

Here’s a full list of the stocks in Jim’s Charitable Trust, the portfolio used by the CNBC Investing Club.



Source

JPMorgan’s top biotech and pharma picks for the second half
Health

JPMorgan’s top biotech and pharma picks for the second half

Biopharmaceutical stocks’ underperformance versus the broader market for a third-straight year is an opportunity for investors, according to JPMorgan. Analyst Chris Schott said in the firm’s June outlook for biopharma that the sector’s poor performance can be traced back to concerns over President Donald Trump’s tariffs and his ” most favored nation ” executive order. […]

Read More
How twin sister triathletes doubled down on sports success to raise health-startup millions from investors
Health

How twin sister triathletes doubled down on sports success to raise health-startup millions from investors

During their last year of completing work for doctoral degrees in physiology, twin sisters Michal Mor and Merav Mor started to compete in Ironman triathlon races. The demand for peak fitness led them to the realize the importance of understanding personal metabolism, and the lack of data being collected on it through devices accessible to […]

Read More
It’s not just AI — China’s quickly gaining an edge over the U.S. in biotech
Health

It’s not just AI — China’s quickly gaining an edge over the U.S. in biotech

Two graduate students research chemical products in a laboratory in Xiwangzhuang Town, Zaozhuang City, Shandong province of China, on Dec. 26, 2023. Nurphoto | Nurphoto | Getty Images BEIJING — For all the attention on U.S.-China competition in artificial intelligence, new studies point to China’s rapid rise in biotechnology, especially for drug and agricultural development. […]

Read More